Abstract:Novel bifunctional thienopyridine derivatives linked by an ester bond demonstrate simultaneous targeting of FXa and P2Y12 receptors. These compounds act as mutual prodrugs, combining anticoagulant and antiplatelet activity in a single molecule. This approach offers potential advantages in the treatment of cardiovascular disease through simplified administration and synergistic therapeutic effects. Thienopyridine derivatives are specifically designed for utilization in antithrombotic therapy to help combat cardiovascular disorders linked to thrombosis. This study introduces new thienopyridine derivatives with superior therapeutic efficacy through synergies by dual functional compounds, developed as antithrombotic agents. Through computational design, we discovered 32 compounds out of a library of 100 compounds that exhibit efficacy. The compounds are synthesized by multiple steps and subsequently purified using chromatographic procedures to achieve a purity level of >99%. Using the ADP‐induced platelet aggregation assay, we have found 4 active test compounds (ACG‐0173‐19, ACG‐0173‐37, ACG‐A‐04, and ACG‐B‐03) out of a total of 32 compounds. On the other hand, ACG‐0173‐19, ACG‐0173‐37, ACG‐A‐04, and ACG‐B‐03 have demonstrated the highest percentage activity on factor Xa (FXa) inhibition. The ACG‐A‐04 chemical exhibited the highest hydrophilicity, specifically in terms of its aqueous solubility. It had a solubility of 0.44 mg/mL in pH 5.8, 0.29 mg/L in pH 6.2, and 0.145 mg/L in pH 7.4 buffers. In comparison, the standards APX‐01 (apixaban) and PRG‐01(prasugrel) had lower hydrophilicity. Based on cytotoxicity investigations, it was determined that the test substances do not exhibit harmful effects. The results indicated that the test chemicals can undergo hydrolysis in blood plasma rather than in other organs. Among the four test drugs, ACG‐1073‐19 exhibited an unbound fraction of 44.1%, which is twice as high as the standards (apixaban). ACG‐1073‐37 demonstrates superior plasma protein binding (33.2%) compared to all other test compounds. The compounds resulted in a higher expression of CD61, CD42b, and CD62P in platelets compared to the control. The ACG‐1073‐37 molecule had a Caco‐2 permeability of 51%, which is extremely close to the Caco‐2 permeability of the control medicines (55% for APX‐01 and 62% for PRG‐01). Through the assessment of microsomal stability, it was determined that ACG‐1073‐37 and ACG‐A‐04 exhibited metabolic stability for 42.4 and 34.14 min, respectively.

Synthesis and Antithrombotic Activity of 3-Aryl-1,2,3,4-oxatriazole-5-imine-coupled Aspirin

Synthesis, Crystal Structures and Xanthine Oxidase Inhibitory Activity of 2-(Benzylthio)-5-[1-(4-Fluorobenzyl)-3-Phenyl-1H-Pyrazol-5-Yl]-1,3,4-Oxadiazoles Derivatives

Synthesis, Structural Characterization, Hirshfeld Surface, DFT Calculation and Antifungal Activity of Novel Quinoline Carbonothioate Compounds

Novel Synthesis Approach and Antiplatelet Activity Evaluation of 6-Alkylamino-2,4-dialkyl(aryl)thiopyrimidines

Synthesis of N-6-Alkyl(Aryl)-2-Alkyl(Aryl)Thioadenosines As Antiplatelet Agents

Synthesis of new class dipeptide analogues with improved permeability and antithrombotic activity.

Synthesis, Molecular Docking, and Hemorheological Activity of New 4-(Thien-2-yl)-3-aminopyridine-2(1H)-one Derivatives

Synthesis and Evaluation of Novel Nitric Oxide-Donating Ligustrazine Derivatives as Potent Antiplatelet Aggregation Agents

Appropriate prophylactic antibiotic use in plastic surgery: the time has come.

Thymic "nurse" cells express extracellular matrix proteins.

Synthesis of Novel 3-Butylphthalide Derivatives Containing Isopentenylphenol Moiety as Potential Antiplatelet Agents for the Treatment of Ischemic Stroke

Synthesis and evaluation of L-quebrachitol derivatives against platelet aggregation

Synthesis of 2-Alkoxy-N-6-alkyl Adenosine Compounds and Their Anti-platelet Aggregation Activity

Synthesis, characterization and thrombolytic activity evaluation of novel pyrazolo[3,4- b ]pyridine-4-carbohydrazide derivatives

New Approach to Synthesize Symmetrical and Unsymmetrical 6-(N-alkyl(aryl)amino)- and 6-(N,n-dialkyl(aryl)amino)-2,4-bis(alkyl(aryl)thio)pyrimidines As Anti-Platelet Agents

Synthesis Of Ligustrazine-Aromatic Acid Derivatives And Their Inhibitory Effect On Platelet Aggregation

A New Class of Anti-Thrombosis Hexahydropyrazino-[1′,2′:1,6]Pyrido-[3,4-b]-indole-1,4-dions: Design, Synthesis, Log K Determination, and QSAR Analysis

ChemInform Abstract: Novel Synthesis Approach and Antiplatelet Activity Evaluation of 6‐Alkylamino‐2,4‐dialkyl(aryl)thiopyrimidines.

Cleavable Novel Thienopyridine Derivatives as Potent Antithrombotic Agents

Design, Synthesis and Evaluation of Antioxidant and NSAID Derivatives with Antioxidant, Anti-Inflammatory and Plasma Lipid Lowering Effects

Synthesis, Docking, and DFT Studies on Novel Schiff Base Sulfonamide Analogues as Selective COX-1 Inhibitors with Anti-Platelet Aggregation Activity